Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - salmonella typhimurium; thiomersal; aluminium hydroxide gel - parenteral liquid/solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 p; thiomersal mercury other 0.13 mg/ml; aluminium hydroxide gel mineral-aluminium-base other 0.0 p - immunotherapy - horse foal | horse mare (female) | female horse - salmonella typhimurium | vaccine | equine rotavirus

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - salmon pancreas disease virus (spdv) strain f93-125 - emulsion for injection - . - salmon pancreas disease virus (spd) - atlantic salmon - immunological - inactivated vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - salmonella typhimurium - oral solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 undefined - immunotherapy - poultry chicks | turkey poult (young) | chickens | day old chicks | hatchlings | turkeys - day old poults | young turkey - salmonella enteridis | salmonella typhimurium | vaccine | equine rotavirus

European Union - English - EMA (European Medicines Agency)

elanco gmbh - puk-spdv-poly2#1 dna plasmid coding for salmon pancreas disease virus proteins - immunologicals for atlantic salmon, - atlantic salmon - for the active immunisation of atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (sav3).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated salmonella dublin & typhimurium antigens; thiomersal - misc. vaccines or anti sera - inactivated salmonella dublin & typhimurium antigens vaccine-microbial active 0.0 undefined; thiomersal mercury other 0.1 mg/ml - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - salmonella | including b-lactamase producin | salmonellosis

United States - English - NLM (National Library of Medicine)

apotheca company - salmonella enterica subsp. enterica serovar enteritidis (unii: y3v16d4pv4) (salmonella enterica subsp. enterica serovar enteritidis - unii:y3v16d4pv4) - salmonella enterica subsp. enterica serovar enteritidis 30 [hp_x] in 1 ml - indications:   to be used according to standard homeopathic indications. indications: to be used according to standard homeopathic indications.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

elanco gmbh - salmon pancreas disease virus - solution for injection - inactivated viral vaccine - atlantic salmon

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet international bv - salmon pancreas disease virus (strain f93-125) inactivated - emulsion for injection - . - salmon pancreas disease virus (spd); inactivated viral vaccines - atlantic salmon, trout - immunological - inactivated vaccine

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 200 [iu] in 0.09 ml - calcitonin-salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. calcitonin-salmon nasal spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. use of calcitonin-salmon nasal spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin d (400 i.u. per day) intake to retard the progressive loss of bone mass. the evidence of efficacy is based on increases in spinal bone mineral density observed in clinical trials. two randomized, placebo controlled trials were conducted in 325 postmenopausal females [227 calcitonin-salmon nasal spray treated and 98 placebo treated] with spinal, forearm or femoral bone mineral density (bmd) at least one standard deviation below normal for healthy premenopausal females. these studies conducted over two years demonstrated that 2

United States - English - NLM (National Library of Medicine)

sandoz inc - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 200 [iu] - calcitonin-salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. calcitonin-salmon nasal spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4)] . - calcitonin-salmon nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1)] . pregnancy category c: risk summary there are no adequate an